NCT05047783 - Masitinib in Patients With Symptomatic Mild to Moderate COVID-19 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 23, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions

Covid19SARS-CoV2 InfectionCoronavirus Disease 2019

Interventions

DRUG

Masitinib Mesylate

3CL-protease inhibitor

DRUG

Placebo

Trial Locations (6)

NOT_YET_RECRUITING

Intensive Care Unit, CHU Gabriel-Montpied, Clermont-Ferrand

RECRUITING

Gabrichevsky Institute of Epidemiology and Microbiology, Moscow

RECRUITING

Scientific Research Center Eco-Safety, Saint Petersburg

RECRUITING

City Clinical Hospital No. 14, Yekaterinburg

RECRUITING

Netcare Jakaranda Hospital, Pretoria

RECRUITING

Langeberg Clinical Trials, Cape Town